All In Biotech

Drug Trial Radar · NCT02049957

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestrant

Last checked: Nov 20, 2026Latest source record: Feb 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

118

Actual

Start

Feb 13, 2014

Primary completion

Jun 29, 2018

Study completion Jun 29, 2018

Sponsor

Lead sponsor
Calithera Biosciences, IncIndustry
Sponsor type
Industry
First posted
Jan 30, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1b/2 study of the safety and efficacy of sapanisertib (MLN0128) in combination with exemestane or fulvestrant therapy in women with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced or metastatic breast cancer who progressed on treatment with everolimus in combination with exemestane or fulvestrant.

Conditions

  • Breast Cancer

Interventions

  • SapanisertibDrug

    Sapnisertib capsules

  • FulvestrantDrug

    Fulvestrant IM injection.

  • ExemestaneDrug

    Exemestane tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: First dose of study drug through 30 days after the last dose (Up to 52 months)
  2. Phase 2: Clinical Benefit Rate at 16 Weeks (CBR-16)Time frame: Week 16

Locations

40 sites in 3 countries. Site status is shown where the registry gives one.

  • Los Angeles Hematology

    Los Angeles, California

  • University of California at San Francisco (PARENT)

    San Francisco, California

  • Santa Barbara Hematology Oncology Medical Group, Inc.

    Santa Barbara, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Rocky Mountain Cancer Centers, LLP

    Lakewood, Colorado

  • Mount Sinai Medical Center

    Miami Beach, Florida

  • Florida Cancer Research Institute

    Plantation, Florida

  • University of Kansas Medical Center Research Institute, Inc.

    Westwood, Kansas

  • Holy Cross Hospital

    Silver Spring, Maryland

  • Henry Ford Medical Center

    Novi, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Herbert Irving Comprehensive Cancer Center

    New York, New York

  • Weill Cornell Medical College New York Presbyterian Hospital

    New York, New York

  • Eastchester Center for Cancer Care / BRANY

    The Bronx, New York

  • University of Cincinnati Physicians Company, LLC

    Cincinnati, Ohio

  • University Hospitals of Cleveland

    Cleveland, Ohio

  • Erlanger Medical Center

    Chattanooga, Tennessee

  • Texas Oncology, P.A. - Beaumont

    Beaumont, Texas

  • Texas Oncology, P.A.

    Dallas, Texas

  • UT Southwestern Medical Center

    Dallas, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Millennium Oncology

    Houston, Texas

  • Texas Health Physicians Group

    Plano, Texas

  • Cancer Care Network of South Texas - SAT&BC

    San Antonio, Texas

  • Texas Oncology, P.A. - Tyler

    Tyler, Texas

  • Virginia Oncology Associates - Hampton

    Chesapeake, Virginia

  • Oncology and Hematology Assoc. of SW VA, Inc.

    Salem, Virginia

  • West Virginia University

    Morgantown, West Virginia

  • UZ Antwerpen

    Antwerp, Belgium

  • Institut Jules Bordet

    Brussels, Belgium

  • Universitair Ziekenhuis Brussel

    Brussels, Belgium

  • GHdC Notre Dame

    Charleroi, Belgium

  • Centre Hospitalier de l'Ardenne

    Libramont, Belgium

  • GZA Ziekenhuizen - Campus Sint-Augustinus

    Wilrijk, Belgium

  • Centre Francois Baclesse

    Caen, Calvados, France

  • Centre Catherine de Sienne

    Nantes, Loire Atlantique, France

  • Clinique Victor Hugo - Centre Jean Bernard

    Le Mans, Sarthe, France

  • Institut Sainte Catherine

    Avignon, Vaculuse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.